Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: A descriptive cohort study

Lupus

Volumn 24, Issue 13, 2015, Pages 1384-1391

  Leroux, M ^a   Desveaux, C ^a   Parcevaux, M ^b   Julliac, B ^c   Gouyon, J B ^a   Dallay, D ^c   Pellegrin, J L ^c   Boukerrou, M ^a   Blanco, P ^c   Lazaro, E ^c  

^a Pole Femme Mere Enfant ^*  (France)

^b Department of Anesthesiology and Critical Care Gabriel Martin Hospital   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

hydroxychloroquine; intrauterine growth restriction; pregnancy; prematurity; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; HYDROXYCHLOROQUINE; PREDNISONE; ANTIRHEUMATIC AGENT; GLUCOCORTICOID;

ADULT; ARTICLE; COHORT ANALYSIS; CONGENITAL MALFORMATION; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FETUS OUTCOME; HEMATOLOGIC DISEASE; HUMAN; INTENSIVE CARE UNIT; INTRAUTERINE GROWTH RETARDATION; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PLEURISY; PREECLAMPSIA; PREGNANT WOMAN; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS SYNDROME; RETROSPECTIVE STUDY; RISK FACTOR; SEPTIC SHOCK; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TWIN PREGNANCY; UNPLANNED PREGNANCY; VASCULAR DISEASE; CHEMICALLY INDUCED; FETAL GROWTH RETARDATION; GESTATIONAL AGE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREMATURITY; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIRHEUMATIC AGENTS; COHORT STUDIES; FEMALE; FETAL GROWTH RETARDATION; GESTATIONAL AGE; GLUCOCORTICOIDS; HUMANS; HYDROXYCHLOROQUINE; INFANT, PREMATURE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PREDNISONE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREMATURE BIRTH; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84945254171     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315591027     Document Type: Article

References (49)

1. Stojan G, Baer AN,. Flares of systemic lupus erythematosus during pregnancy and the puerperium: prevention, diagnosis and management. Expert Rev Clin Immunol 2012; 8: 439-453.
2. Vinet E, Labrecque J, Pineau CA, et al. A population-based assessment of live births in women with systemic lupus erythematosus. Ann Rheum Dis 2012; 71: 557-559.
3. Barnabe C, Faris PD, Quan H,. Canadian pregnancy outcomes in rheumatoid arthritis and systemic lupus erythematosus. Int J Rheumatol 2011; 2011: 345727-345727.
4. Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010; 62: 863-868.
5. Zero-Time Assessment. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med 1991; 324: 150-154.
6. Tsakonas E, Joseph L, Esdaile JM, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998; 7: 80-85.
7. Alarcón GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007; 66: 1168-1172.
8. McChesney EW,. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med 1983; 75 (1): 11-18.
9. Parke AL,. Antimalarial drugs, systemic lupus erythematosus and pregnancy. J Rheumatol 1988; 15: 607-610.
10. Parke A, West B,. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 1996; 23: 1715-1718.
11. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA,. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20-28.
12. Sperber K, Hom C, Chao CP, Shapiro D, Ash J,. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol 2009; 7: 9-9.
13. Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001; 10: 401-404.
14. Clowse MEB, Magder L, Witter F, Petri M,. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006; 54: 3640-3647.
15. Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003; 48: 3207-3211.
16. Costedoat-Chalumeau N, Amoura Z, Huong DLT, Lechat P, Piette J-C,. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev 2005; 4: 111-115.
17. Buchanan NM, Toubi E, Khamashta MA, Lima F, Kerslake S, Hughes GR,. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 1996; 55: 486-488.
18. Parke A,. Antimalarial drugs and pregnancy. Am J Med 1988; 85(4): 30-33.
19. Motta M, Tincani A, Faden D, Zinzini E, Chirico G,. Antimalarial agents in pregnancy. Lancet 2002; 359: 524-525.
20. Klinger G, Morad Y, Westall CA, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 2001; 358: 813-814.
21. Barsalou J, Jaeggi E, Tian SY, Hamilton RM, Laskin CA, Silverman ED,. A149: does prenatal exposure to antimalarial decrease the risk of neonatal lupus: a Bayesian perspective. Arthritis Rheumatol 2014; 66 (Suppl 3): S193-S193.
22. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126 (1): 76-82.
23. Proceedings and abstracts of the 4th International Conference on Sex Hormones, Pregnancy and the Rheumatic Disease, September 20-22, 2004, Stresa, Italy. Lupus 2004; 13: 625-763.
24. Al-Herz A, Schulzer M, Esdaile JM,. Survey of antimalarial use in lupus pregnancy and lactation. J Rheumatol 2002; 29: 700-706.
25. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
26. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH,. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
27. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
28. Meyer O,. Making pregnancy safer for patients with lupus. Joint Bone Spine 2004; 71: 178-182.
29. Mamelle N, Munoz F, Grandjean H,. Fetal growth from the AUDIPOG study. I. Establishment of reference curves. J Gynecol Obstet Biol Reprod (Paris) 1996; 25: 61-70.
30. Mamelle N, Munoz F, Martin JL, Laumon B, Grandjean H,. Fetal growth from the AUDIPOG study. II. Application for the diagnosis of intrauterine growth retardation. J Gynecol Obstet Biol Reprod (Paris) 1996; 25: 71-77.
31. Gladman DD, Goldsmith CH, Urowitz MB, et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 1994; 21: 1468-1471.
32. Le Guern V, Pannier E, Goffinet F,. Systemic lupus erythematosus and pregnancy. La Presse Médicale 2008; 37: 1627-1635.
33. D'Cruz DP, Khamashta MA, Hughes GRV,. Systemic lupus erythematosus. Lancet 2007; 369: 587-596.
34. Lê Thi Huong D, Wechsler B, Piette JC, Blétry O, Godeau P,. French register of lupus in pregnancy: the evaluation. Groupe d'étude sur la grossesse lupique. Rev Med Interne 1994; 15: 305-317.
35. Clark CA, Spitzer KA, Nadler JN, Laskin CA,. Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol 2003; 30: 2127-2132.
36. Lima F, Buchanan NM, Khamashta MA, Kerslake S, Hughes GR,. Obstetric outcome in systemic lupus erythematosus. Semin Arthritis Rheum 1995; 25: 184-192.
37. Yasmeen S, Wilkins EE, Field NT, Sheikh RA, Gilbert WM,. Pregnancy outcomes in women with systemic lupus erythematosus. J Matern Fetal Med 2001; 10: 91-96.
38. Petri M, Howard D, Repke J, Goldman DW,. The Hopkins Lupus Pregnancy Center: 1987-1991 update. Am J Reprod Immunol 1992; 28: 188-191.
39. INSERM. French national perinatal survey. INSERM, 2010.
40. Gouyon J-B, Iacobelli S, Ferdynus C, Bonsante F,. Neonatal problems of late and moderate preterm infants. Semin Fetal Neonatal Med 2012; 17: 146-152.
41. Melamed N, Klinger G, Tenenbaum-Gavish K, et al. Short-term neonatal outcome in low-risk, spontaneous, singleton, late preterm deliveries. Obstet Gynecol 2009; 114 (2 Pt 1): 253-260.
42. Hallowell SG, Spatz DL,. The relationship of brain development and breastfeeding in the late-preterm infant. J Pediatr Nurs 2012; 27: 154-162.
43. Morse SB, Zheng H, Tang Y, Roth J,. Early school-age outcomes of late preterm infants. Pediatrics 2009; 123: e622-e629.
44. Fox R,. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 1996; 5 (Suppl 1): S4-S10.
45. Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R,. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011; 186: 4794-4804.
46. Petri M,. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996; 5 (Suppl 1): S16-S22.
47. Resnik R,. Intrauterine growth restriction. Obstet Gynecol 2002; 99: 490-496.
48. Ostensen M, Clowse M,. Pathogenesis of pregnancy complications in systemic lupus erythematosus. Curr Opin Rheumatol 2013; 25: 591-596.
49. López-Farfán JA, Martínez-Marín DG, Van Der Heyden-Pardo T,. Uterine artery score in patients with systemic lupus erythematous as a predictor of intrauterine growth restriction. Ginecol Obstet Mex 2011; 79: 137-142.